Is surgery at progression a prognostic marker for improved 6-month progression-free survival or overall survival for patients with recurrent glioblastoma?

Historically, the North American Brain Tumor Consortium used 6-month progression-free survival (PFS6) as the primary outcome for recurrent glioma phase II clinical trials. In some trials, a subset of patients received the trial treatment before surgery to assess tumor uptake and biological activity....

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Clarke†, Jennifer L., Ennis†, Michele M., Yung, W. K. Alfred, Chang, Susan M., Wen, Patrick Y., Cloughesy, Timothy F., DeAngelis, Lisa M., Robins, H. Ian, Lieberman, Frank S., Fine, Howard A., Abrey, Lauren, Gilbert, Mark R., Mehta, Minesh, Kuhn, John G., Aldape, Kenneth D., Lamborn, Kathleen R., Prados, Michael D.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Oxford University Press 2011
Gaiak:
Clinical Investigations
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC3177665/
https://ncbi.nlm.nih.gov/pubmed/21813511
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nor110
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak